After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat ...

Earlier on Monday, Sun Pharma reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in Q2 FY2025.

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

What is the Sun Pharmaceuticals Industries Ltd share price today? The Sun Pharmaceuticals Industries Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1869.75 today. What is the Market Cap ...

Stay informed with the Sun Pharma Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of ...